CO5580773A2 - Rosuvastatina en estados pre dementes - Google Patents
Rosuvastatina en estados pre dementesInfo
- Publication number
- CO5580773A2 CO5580773A2 CO04035705A CO04035705A CO5580773A2 CO 5580773 A2 CO5580773 A2 CO 5580773A2 CO 04035705 A CO04035705 A CO 04035705A CO 04035705 A CO04035705 A CO 04035705A CO 5580773 A2 CO5580773 A2 CO 5580773A2
- Authority
- CO
- Colombia
- Prior art keywords
- rosuvastatina
- dement
- states
- patient
- dementia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103509A SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Rosuvastatin in pre demented states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5580773A2 true CO5580773A2 (es) | 2005-11-30 |
Family
ID=20285721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04035705A CO5580773A2 (es) | 2001-10-19 | 2004-04-19 | Rosuvastatina en estados pre dementes |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060229321A1 (enExample) |
| EP (1) | EP1446123A1 (enExample) |
| JP (1) | JP2005505605A (enExample) |
| KR (1) | KR20040058201A (enExample) |
| CN (1) | CN1604780A (enExample) |
| AR (1) | AR036891A1 (enExample) |
| BR (1) | BR0213434A (enExample) |
| CA (1) | CA2463597A1 (enExample) |
| CO (1) | CO5580773A2 (enExample) |
| HU (1) | HUP0401798A3 (enExample) |
| IL (1) | IL161380A0 (enExample) |
| IS (1) | IS7218A (enExample) |
| MX (1) | MXPA04003631A (enExample) |
| NO (1) | NO20041840L (enExample) |
| PL (1) | PL369573A1 (enExample) |
| RU (1) | RU2004112422A (enExample) |
| SE (1) | SE0103509D0 (enExample) |
| WO (1) | WO2003032995A1 (enExample) |
| ZA (1) | ZA200402844B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396927B2 (en) | 2003-08-28 | 2008-07-08 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| WO2005051921A1 (en) | 2003-11-24 | 2005-06-09 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| CN1894221B (zh) | 2003-12-02 | 2012-08-08 | 特瓦制药工业有限公司 | 用于表征罗苏伐他汀的参照标准品 |
| WO2006017357A1 (en) | 2004-07-13 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step |
| TWI345562B (en) | 2005-02-22 | 2011-07-21 | Teva Pharma | Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof |
| KR20070062996A (ko) | 2005-08-16 | 2007-06-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | 결정성 로수바스타틴 중간체 |
| WO2012073256A1 (en) | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
| AR022462A1 (es) * | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
-
2001
- 2001-10-19 SE SE0103509A patent/SE0103509D0/xx unknown
-
2002
- 2002-10-17 AR ARP020103895A patent/AR036891A1/es not_active Application Discontinuation
- 2002-10-18 RU RU2004112422/14A patent/RU2004112422A/ru not_active Application Discontinuation
- 2002-10-18 EP EP02783893A patent/EP1446123A1/en not_active Withdrawn
- 2002-10-18 PL PL02369573A patent/PL369573A1/xx not_active Application Discontinuation
- 2002-10-18 MX MXPA04003631A patent/MXPA04003631A/es not_active Application Discontinuation
- 2002-10-18 HU HU0401798A patent/HUP0401798A3/hu unknown
- 2002-10-18 IL IL16138002A patent/IL161380A0/xx unknown
- 2002-10-18 BR BR0213434-9A patent/BR0213434A/pt not_active Application Discontinuation
- 2002-10-18 CN CNA028253477A patent/CN1604780A/zh active Pending
- 2002-10-18 US US10/492,971 patent/US20060229321A1/en not_active Abandoned
- 2002-10-18 KR KR10-2004-7005585A patent/KR20040058201A/ko not_active Withdrawn
- 2002-10-18 CA CA002463597A patent/CA2463597A1/en not_active Abandoned
- 2002-10-18 JP JP2003535798A patent/JP2005505605A/ja active Pending
- 2002-10-18 WO PCT/SE2002/001911 patent/WO2003032995A1/en not_active Ceased
-
2004
- 2004-04-13 IS IS7218A patent/IS7218A/is unknown
- 2004-04-15 ZA ZA200402844A patent/ZA200402844B/en unknown
- 2004-04-19 CO CO04035705A patent/CO5580773A2/es not_active Application Discontinuation
- 2004-05-05 NO NO20041840A patent/NO20041840L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20060229321A1 (en) | 2006-10-12 |
| EP1446123A1 (en) | 2004-08-18 |
| PL369573A1 (en) | 2005-05-02 |
| HUP0401798A3 (en) | 2005-06-28 |
| RU2004112422A (ru) | 2005-04-10 |
| BR0213434A (pt) | 2004-11-09 |
| HUP0401798A2 (hu) | 2005-01-28 |
| ZA200402844B (en) | 2005-01-24 |
| CN1604780A (zh) | 2005-04-06 |
| CA2463597A1 (en) | 2003-04-24 |
| SE0103509D0 (sv) | 2001-10-19 |
| WO2003032995A1 (en) | 2003-04-24 |
| IL161380A0 (en) | 2004-09-27 |
| JP2005505605A (ja) | 2005-02-24 |
| WO2003032995A8 (en) | 2004-06-03 |
| AR036891A1 (es) | 2004-10-13 |
| NO20041840L (no) | 2004-05-05 |
| KR20040058201A (ko) | 2004-07-03 |
| MXPA04003631A (es) | 2004-07-30 |
| IS7218A (is) | 2004-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2545205T3 (es) | Combinación de azelastina y ciclesonida | |
| BR0113200A (pt) | Combinação terapêutica | |
| NO20045434L (no) | En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom | |
| EA200100572A1 (ru) | Способ применения ингибитора циклооксигеназы-2 и одного или нескольких противоопухолевых лекарственных средств в качестве комбинированного способа лечебного воздействия при лечении неоплазии | |
| PT840601E (pt) | Thip para o tratamento de desordens do sono | |
| AR013742A1 (es) | Metodo para el tratamiento de la hipercolesterolemia con polidialilamina no substituida | |
| FI973868A7 (fi) | D2-vitamiini- tai D4-vitamiinijohdannaisten käyttö sekundaarisen hyper paratyreoosin hoitoon tarkoitettu lääkkeen valmistuksessa | |
| ATE344029T1 (de) | Behandlung von typ ii diabetes mit dipeptidyl- peptidase-iv-hemmern | |
| BRPI0111116B8 (pt) | imitadores de trombopoietina | |
| DK0695189T3 (da) | Behandling af inflammatorisk tarmsygdom med IFN-gammainhibitorer | |
| BR0111913A (pt) | Análogos de gabapentina para distúrbios do sono | |
| GB0002336D0 (en) | Medicaments | |
| DE59608698D1 (de) | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden, enthaltend Sympthomimeticum und Pantothenol und/oder Pantothensäure | |
| BR0110506A (pt) | Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose | |
| AR036891A1 (es) | Rosuvastatina en estados predemenciales | |
| BR9809673A (pt) | Derivados de triptolida úteis no tratamento de doenças autoimunes | |
| UY26171A1 (es) | Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía | |
| BR0016941A (pt) | Derivados de aminometil-fenil-ciclohexanona | |
| AR039162A1 (es) | Formulaciones de venlafaxina de liberacion extendida | |
| TR200103561T2 (tr) | Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları | |
| BR9910185A (pt) | Uso de um composto, e, processo para o tratamento de um paciente que sofre de, ou em risco de, uma doença micobacteriana | |
| BR0313230A (pt) | Uso de carboxamidas para o tratamento de tinido | |
| AR030660A1 (es) | Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12 | |
| CO5590922A2 (es) | Uso de istradefilina (kw-6002) para el tratamiento de trastornos de la conducta | |
| ES2101311T3 (es) | Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |